Zogenix receives US approval for subcutanous needle-free sumatriptan
17 July 2009
John Davis
Please Login to read the full article.
17 July 2009
John Davis
john.davis@informa.com
Zogenix's needle-free, single-use, subcutaneous migraine product, Sumavel DosePro (sumatriptan), has been approved for marketing in the US.
It is the private US company's first product, and the first approval for the needle-free delivery system formerly known as Intraject. The delivery system...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Zogenix's long-acting hydrocodone meets chronic pain endpoint, ready for 2012 filing
- Zogenix, Duract in deal for work on once-monthly risperidone, to contrast with J&J blockbuster
- Zogenix, Battelle agree to work toward out-licensing needle-free injection platform
- Zogenix adds $60 million equity to take lead to NDA and fund operations until 2013
COMMENT
Other Informa Comment
EVENTS
26 February 2012
Vancouver Convention Centre | Vancouver, BC, Canada
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
